Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the PEACE-1 and STAMPEDE (NCT00268476) trials, both presented at this year’s European Society for Medical Oncology (ESMO) 2021 congress. The first study discussed is the STAMPEDE trial is a randomized, controlled trial recruiting in the UK and Switzerland that aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-naïve prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control arm. The second study discussed, PEACE-1 (NCT01957436) is a multi-center phase III study to compare the clinical benefit of androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.